Mind the Gaps: Economic, Structural and Human Dimensions of
Access and Adherence to HIV/AIDS Prevention

Date: Monday, 27 October
 12:00-14:00 – Lunch provided
Venue: CTICC Room 1.63-1.64

Hosting partners:
     International AIDS Vaccine Initiative (IAVI)
     U.S. Military HIV Research Program (MHRP)
     HIV Vaccine Trials Network (HVTN)
     Joint United Nations Programme on HIV/AIDS (UNAIDS)
     The Foundation for AIDS Research (amfAR)


Alex Coutinho, Executive Director, Infectious Diseases Institute, Makerere University, Uganda
Glenda Gray, President, South African Medical Research Council


It will be particularly important for future HIV/AIDS vaccines to demonstrate their potential impact and cost-effectiveness, and their suitability for public health programs, early in the research and development (R&D) process to ensure they will be accessible to those in need. The formulations of and the vaccination approaches for HIV/AIDS vaccines are likely to be more complex than with other vaccines to date (vectors, adjuvants; different vaccines for prime and boost). Other HIV prevention options are progressing towards licensure, and the competition with other diseases for funding is increasing as is the need to assure optimal use of the funding available. The health care systems in most affected countries may lack sufficient infrastructure and personnel to optimize access. And the target populations for HIV/AIDS vaccination can be particularly difficult to reach and motivate given barriers like cultural and social norms, gender inequity, stigma, discrimination and punitive laws, as well as individual beliefs, perceptions and behaviors. HIV/AIDS vaccine R&D should happen in close and constant interaction with the people who most need a vaccine, as well as the governments and others who will fund, decide, and/or plan future vaccination programs.

This session will help advance these interactions by exploring the interdependencies between product R&D and access.


The Potential Impact and Cost-Effectiveness of AIDS Vaccines in Reducing HIV Incidence as Part of the UNAIDS Enhanced Investment Framework, Margie McGlynn, President and CEO, IAVI

Criteria for Governments to Consider and Fund AIDS Vaccination Programs, Fareed Abdullah, CEO, South African National AIDS Council

Building on RV144: How Bio-Manufacturing Initiative in Thailand Could Make an HIV Vaccine for Southeast Asia, Robert J. O'Connell, Product Manager, HIV Vaccines, MHRP and Chief, Dept. of Retrovirology, AFRIMS, Thailand

Learnings from HPV Vaccination in South Africa, Helen Rees, Executive Director, Wits Institute of Reproductive Health and HIV, University of Witwatersrand, South Africa

Social and Behavioral Opportunities for AIDS Vaccines – Learning from Experience with Other HIV Prevention and Treatment Programs for Most Affected Populations, Peter Godfrey-Faussett, Senior Science Adviser, UNAIDS

Q&A, with Kent Klindera, Director, GMT Initiative, amfAR, joining the panel.